NOVARTIS AG-SPONSORED ADR (NVS) Stock Price & Overview
NYSE:NVS • US66987V1098
The current stock price of NVS is 153.44 USD. Today NVS is down by -0.53%. In the past month the price decreased by -4.8%. In the past year, price increased by 40.69%.
NVS Key Statistics
- Market Cap
- 294.419B
- P/E
- 16.99
- Fwd P/E
- 16.88
- EPS (TTM)
- 9.03
- Dividend Yield
- 2.96%
NVS Stock Performance
NVS Stock Chart
NVS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NVS. When comparing the yearly performance of all stocks, NVS is one of the better performing stocks in the market, outperforming 87.09% of all stocks.
NVS Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NVS. Both the health and profitability get an excellent rating, making NVS a very profitable company, without any liquidiy or solvency issues.
NVS Earnings
On February 4, 2026 NVS reported an EPS of 2.04 and a revenue of 13.34B. The company missed EPS expectations (-0.17% surprise) and missed revenue expectations (-4.89% surprise).
NVS Forecast & Estimates
34 analysts have analysed NVS and the average price target is 156 USD. This implies a price increase of 1.67% is expected in the next year compared to the current price of 153.44.
For the next year, analysts expect an EPS growth of 0.69% and a revenue growth 2.75% for NVS
NVS Groups
Sector & Classification
NVS Financial Highlights
Over the last trailing twelve months NVS reported a non-GAAP Earnings per Share(EPS) of 9.03. The EPS increased by 14.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.83% | ||
| ROA | 12.6% | ||
| ROE | 30.31% | ||
| Debt/Equity | 0.64 |
NVS Ownership
NVS Latest News, Press Relases and Analysis
NVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.34 | 286.575B | ||
| PFE | PFIZER INC | 8.9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.05B | ||
| ZTS | ZOETIS INC | 16.34 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.461B | ||
| VTRS | VIATRIS INC | 5.39 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVS
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
IPO: 2001-05-07
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056 CH
CEO: Vasant (Vas) Narasimhan
Employees: 75883
Phone: 41613241111
NOVARTIS AG-SPONSORED ADR / NVS FAQ
What does NOVARTIS AG-SPONSORED ADR do?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
What is the current price of NVS stock?
The current stock price of NVS is 153.44 USD. The price decreased by -0.53% in the last trading session.
Does NOVARTIS AG-SPONSORED ADR pay dividends?
NOVARTIS AG-SPONSORED ADR (NVS) has a dividend yield of 2.96%. The yearly dividend amount is currently 4.02.
What is the ChartMill technical and fundamental rating of NVS stock?
NVS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the number of employees for NOVARTIS AG-SPONSORED ADR?
NOVARTIS AG-SPONSORED ADR (NVS) currently has 75883 employees.
Can you provide the upcoming earnings date for NOVARTIS AG-SPONSORED ADR?
NOVARTIS AG-SPONSORED ADR (NVS) will report earnings on 2026-04-27.
What is the outstanding short interest for NOVARTIS AG-SPONSORED ADR?
The outstanding short interest for NOVARTIS AG-SPONSORED ADR (NVS) is 0.44% of its float.